Biblio

Found 14 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is F  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
F
H. Fujiwara, Yokota, H., Monk, B. J., Treilleux, I., Devouassoux-Shisheboran, M., Davis, A., Kim, J. - W., Mahner, S., Stany, M., Pignata, S., Ray-Coquard, I., and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S96-101, 2014.
M. Leonard Friedlander, Stockler, M., O'Connell, R., Voysey, M., Oza, A. M., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K. Marie, Butow, P., King, M. Trudy, and Group, S. Benefit St, Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer Intergroup symptom benefit study, Int J Gynecol Cancer, vol. 24, pp. 857-64, 2014.
M. Leonard Friedlander, Trimble, E. L., Tinker, A., Alberts, D. S., Åvall-Lundqvist, E., Brady, M. F., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., Vergote, I. B., Beale, P., Bekkers, R., Calvert, P., Copeland, L., Glasspool, R. M., Gonzalez-Martin, A., Katsaros, D., Kim, J. Won, Miller, B., Provencher, D. M., Rubinstein, L., Atri, M., Zeimet, A. G., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., Clinical trials in recurrent ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.
M. Leonard Friedlander, Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., and Harnett, P., Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer, Int J Gynecol Cancer, vol. 17, pp. 350-8, 2007.
M. Leonard Friedlander, Covens, A., Glasspool, R. M., Hilpert, F., Kristensen, G. B., Kwon, S., Selle, F., Small, W., Witteveen, E., and Russell, P., Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S78-82, 2014.
M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial., Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
G. Freyer, Geay, J. - F., Touzet, S., Provencal, J., Weber, B., Jacquin, J. P., Ganem, G., Tubiana-Mathieu, N., Gisserot, O., and Pujade-Lauraine, E., Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study, Ann Oncol, vol. 16, pp. 1795-800, 2005.
G. Freyer and Tinker, A. V., Clinical trials and treatment of the elderly diagnosed with ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 776-81, 2011.
P. M. Flynn, Paul, J., Cruickshank, D. J., and Group, S. Gynaecolog, Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?, Gynecol Oncol, vol. 86, pp. 354-7, 2002.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
G. F. Fleming, Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., and Burks, R. T., Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, vol. 22, pp. 2159-66, 2004.
J. M. Ferrero, Weber, B., Geay, J. - F., Lepille, D., Orfeuvre, H., Combe, M., Mayer, F., Leduc, B., Bourgeois, H., Paraiso, D., and Pujade-Lauraine, E., Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial, Ann Oncol, vol. 18, pp. 263-8, 2007.
G. Ferrandina, Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., and Scambia, G., Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer, Gynecol Oncol, vol. 109, pp. 187-93, 2008.
A. Fagotti, Fanfani, F., Vizzielli, G., Gallotta, V., Ercoli, A., Paglia, A., Costantini, B., Vigliotta, M., Scambia, G., and Ferrandina, G., Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?, Gynecol Oncol, vol. 116, pp. 72-7, 2010.